Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.
Clin Cancer Res
; 28(24): 5455-5468, 2022 12 15.
Article
in En
| MEDLINE
| ID: mdl-36048524
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hematologic Neoplasms
/
Proto-Oncogene Proteins c-bcl-2
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2022
Type:
Article
Affiliation country:
China